Taysha Gene Therapies, Inc.

NasdaqGS:TSHA Stock Report

Market Cap: US$395.5m

Taysha Gene Therapies Management

Management criteria checks 4/4

Taysha Gene Therapies' CEO is Sean Nolan, appointed in Dec 2022, has a tenure of 2.08 years. total yearly compensation is $1.52M, comprised of 39.4% salary and 60.6% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $573.89K. The average tenure of the management team and the board of directors is 2.1 years and 3.9 years respectively.

Key information

Sean Nolan

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage39.4%
CEO tenure2.1yrs
CEO ownership0.1%
Management average tenure2.1yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Oct 14

More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Jun 27
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%

Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky

Jun 20

Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

Apr 20
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%

What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Mar 21
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 20

Taysha: Produces Solid Data But Has Abandoned Programs

Feb 06

Taysha Gene Therapies Gets A 'Thumbs Up'

Mar 07

CEO Compensation Analysis

How has Sean Nolan's remuneration changed compared to Taysha Gene Therapies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$23m

Jun 30 2024n/an/a

-US$114m

Mar 31 2024n/an/a

-US$118m

Dec 31 2023US$2mUS$600k

-US$112m

Sep 30 2023n/an/a

-US$214m

Jun 30 2023n/an/a

-US$124m

Mar 31 2023n/an/a

-US$133m

Dec 31 2022US$2mUS$25k

-US$166m

Sep 30 2022n/an/a

-US$161m

Jun 30 2022n/an/a

-US$186m

Mar 31 2022n/an/a

-US$193m

Dec 31 2021US$321kn/a

-US$175m

Sep 30 2021n/an/a

-US$142m

Jun 30 2021n/an/a

-US$106m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$457kn/a

-US$60m

Compensation vs Market: Sean's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.

CEO

Sean Nolan (56 yo)

2.1yrs

Tenure

US$1,522,515

Compensation

Mr. Sean P. Nolan serves as Executive Chairman of Jaguar Gene Therapy, LLC. Mr. Nolan has been Chairman of the board at Taysha Gene Therapies, Inc since March 2020 and serves as its Chief Executive Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Sean Nolan
CEO & Chairman2.1yrsUS$1.52m0.15%
$ 573.9k
Sukumar Nagendran
President2.1yrsUS$1.25m0.12%
$ 482.8k
Kamran Alam
CFO & Corporate Secretary4.4yrsUS$975.40k0.19%
$ 750.3k
Hayleigh Collins
Director of Corporate Communications & Investor Relationsno datano datano data
Tracy Porter
Chief People Officer4yrsno datano data
Frederick Porter
Chief of Staff & Technical Operations Officer2yrsno datano data
Emily McGinnis
Chief Patient & External Affairs Officer and Endpoint & Outcome Development Leadno datano datano data
Sean McAuliffe
Chief Business Officerno datano datano data
Steven Gray
Chief Scientific Advisor of UT Southwestern Gene Therapy Programno datano datano data
Berge Minassian
Chief Medical Advisor of UT Southwestern Gene Therapy Programno datano datano data
Rumana Haque-Ahmed
Chief Regulatory Officerno datano datano data
Meredith Schultz
Chief Medical Officerless than a yearno datano data

2.1yrs

Average Tenure

56yo

Average Age

Experienced Management: TSHA's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sean Nolan
CEO & Chairman4.8yrsUS$1.52m0.15%
$ 573.9k
Sukumar Nagendran
President4.5yrsUS$1.25m0.12%
$ 482.8k
Phillip Donenberg
Independent Director4.4yrsUS$73.82k0.056%
$ 220.2k
Sean Stalfort
Independent Director1.6yrsUS$35.09k0.94%
$ 3.7m
Paul Manning
Board Observer1.6yrsUS$22.81k12.12%
$ 47.9m
Wendy Chung
Independent Scientific Advisory Board3.9yrsno datano data
Deborah Bilder
Independent Scientific Advisory Board3.9yrsno datano data
David Dimmock
Independent Scientific Advisory Board3.9yrsno datano data
Laura Sepp-Lorenzino
Independent Director4.2yrsUS$76.90k0%
$ 0
Alison Long
Independent Director1.2yrsUS$77.96k0%
$ 0
Gerald Lipshutz
Independent Scientific Advisory Board3.9yrsno datano data
Benedikt Schoser
Member of Independent Scientific Advisory Board3.3yrsno datano data

3.9yrs

Average Tenure

59yo

Average Age

Experienced Board: TSHA's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 00:07
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Taysha Gene Therapies, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Keith TapperBMO Capital Markets Equity Research
Yun ZhongBTIG